Santarus, Inc: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial ReportiCD ResearchFebruary 6, 2012 38 Pages - SKU: ICDR6792843 |
| Synopsis ICD Research's Santarus, Inc: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report contains in depth information and data about the company and its operations. The profile contains a company overview, business description, competitive benchmarking, SWOT analysis, key facts, information on products and services, plus information on key news events affecting the company. Summary ICD Research's Santarus, Inc: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report is a crucial resource for industry executives and anyone looking to access key information about Santarus, Inc.. ICD Research's Santarus, Inc: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Scope
Santarus, Inc. (Santarus) is a pharmaceutical company, which develops, produces and markets products for gastrointestinal diseases and disorders. The company's flagship product, Zegerid is a proton pump inhibitor for the treatment of upper gastrointestinal diseases and disorders including gastroesophageal reflux disease (GERD). The company also offers metformin hydrochloride extended release tablets under GLUMETZA brand, which acts as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Santarus distributes its products to a broad base of gastroenterologists, endocrinologists and other physicians across the US. The company is headquartered in California, the US. |
Related Markets
Pharmaceuticals Company Reports
- Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2012
- Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
- Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics
- Partnerships, Licensing, Investments and M&A Deals and Trends for March 2012 in Pharmaceuticals
- Contract Research Organizations (CROs) Market to 2018 - Public-Private Partnerships to Strengthen Research Capacities and Advance Clinical Development Programs

